{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:46:53Z","timestamp":1794008813211,"version":"4.8.0"},"reference-count":37,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2016,5,31]],"date-time":"2016-05-31T00:00:00Z","timestamp":1464652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The aim of this study was to investigate the impact of ageing on serum concentrations of risperidone and 9\u2010hydroxyrisperidone in patients with known <jats:italic><jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>2D6<\/jats:italic> genotype. We included retrospective therapeutic drug monitoring data from 464 genotyped patients with measured serum concentrations of risperidone and 9\u2010hydroxyrisperidone after oral administration. Patients were divided into two age subgroups, that is \u226465 (n = 396) and &gt;65 years (n = 68), and dose\u2010adjusted concentrations (C:D ratios) were compared using multiple linear regression analyses with <jats:italic><jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>2D6<\/jats:italic> genotype and gender as covariates. Moreover, absolute concentrations and prescribed daily doses were compared between age subgroups by simple, univariate Mann\u2013Whitney tests. Age had no effect on C:D ratio of risperidone (<jats:italic>p<\/jats:italic> &gt; 0.4), but C:D ratios of 9\u2010hydroxyrisperidone and risperidone + 9\u2010hydroxyrisperidone (total active moiety) were estimated to be 2.6 and 2.0 times higher in patients &gt;65 <jats:italic>versus<\/jats:italic> \u226465 years (<jats:italic>p<\/jats:italic> &lt; 0.001). Female gender and a <jats:italic><jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>2D6<\/jats:italic> poor metabolizer (<jats:styled-content style=\"fixed-case\">PM<\/jats:styled-content>) genotype were also associated with significantly higher C:D ratio of the total active moiety (<jats:italic>p<\/jats:italic> &lt; 0.01). Despite lower dosing in patients &gt;65 <jats:italic>versus<\/jats:italic> \u226465 years (median 1.5 <jats:italic>versus<\/jats:italic> 3.0 mg\/day, <jats:italic>p<\/jats:italic> &lt; 0.0001), absolute concentration of the total active moiety did not differ between the age subgroups (median 52.5 <jats:italic>versus<\/jats:italic> 47.0 nmol\/L, <jats:italic>p<\/jats:italic> &gt; 0.6). In conclusion, ageing implies significantly increased dose\u2010adjusted serum concentration of risperidone active moiety, and treatment intensity is not generally reduced by halving the oral dose in the elderly. Tolerability of risperidone therapy should therefore be closely monitored in older patients, and female CYP2D6 PMs &gt;65 years might be a particularly vulnerable subgroup of adverse effects.<\/jats:p>","DOI":"10.1111\/bcpt.12614","type":"journal-article","created":{"date-parts":[[2016,5,4]],"date-time":"2016-05-04T16:48:27Z","timestamp":1462380507000},"page":"470-475","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Impact of Ageing on Serum Concentrations of Risperidone and Its Active Metabolite in Patients with Known <i>CYP2D6<\/i> Genotype"],"prefix":"10.1111","volume":"119","author":[{"given":"Espen","family":"Molden","sequence":"first","affiliation":[{"name":"Center for Psychopharmacology Diakonhjemmet Hospital Oslo Norway"},{"name":"Department of Pharmaceutical Biosciences School of Pharmacy University of Oslo Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragnhild Birkeland","family":"Waade","sequence":"additional","affiliation":[{"name":"Center for Psychopharmacology Diakonhjemmet Hospital Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren","family":"Hoff","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Biosciences School of Pharmacy University of Oslo Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tore","family":"Haslemo","sequence":"additional","affiliation":[{"name":"Center for Psychopharmacology Diakonhjemmet Hospital Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,5,31]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"Prescribing information RISPERDAL\u00ae(risperidone) revised 04\/2014.http:\/\/www.jansen.com(last accessed on March 4 2016)."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1409"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2005.03.013"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610206003942"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n1006"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12596"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000239796.21826.39"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245444"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.001230"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.720"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145704004390"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1286287"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000018"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3182489a6f"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200106000-00007"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200208000-00014"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200209000-00004"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200111000-00008"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.2165\/11318030-000000000-00000"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12286"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-973836"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181ee84c7"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130051171"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0289-8"},{"key":"e_1_2_7_26_1","unstructured":"http:\/\/www.reseptregistrert.no(last accessed on March 4 2016)."},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881105053306"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/089198870201500205"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02246543"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-007-0453-7"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.51.1.80"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-946701"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2014.885504"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-012-0556-0"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awr298"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0103"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3182577c43"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000169"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcpt.12614","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.12614","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T17:06:01Z","timestamp":1695747961000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcpt.12614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,31]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1111\/bcpt.12614"],"URL":"https:\/\/doi.org\/10.1111\/bcpt.12614","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,31]]},"assertion":[{"value":"2016-03-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-04-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-05-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}